Contrasting Black Diamond Therapeutics (NASDAQ:BDTX) and Sera Prognostics (NASDAQ:SERA)

Black Diamond Therapeutics (NASDAQ:BDTX) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Institutional and Insider Ownership

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Black Diamond Therapeutics and Sera Prognostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1	2	7	0	2.60
Sera Prognostics	1	0	1	1	2.67

Black Diamond Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 485.11%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 170.94%. Given Black Diamond Therapeutics’ higher probable upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Sera Prognostics.

Volatility and Risk

Black Diamond Therapeutics has a beta of 3.32, suggesting that its stock price is 232% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.

Valuation & Earnings

This table compares Black Diamond Therapeutics and Sera Prognostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70.00 million	1.54	$22.37 million	($0.75)	-2.51
Sera Prognostics	$80,000.00	1,001.04	-$31.93 million	($0.67)	-3.03

Black Diamond Therapeutics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Black Diamond Therapeutics and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Summary

Black Diamond Therapeutics beats Sera Prognostics on 10 of the 15 factors compared between the two stocks.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.